Oryzon Genomics S.A. (ORYZF)

Oryzon Genomics Statistics

Total Valuation

Oryzon Genomics has a market cap or net worth of 290.97 million. The enterprise value is 275.56 million.

Market Cap	290.97M
Enterprise Value	275.56M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	78.85M
Shares Outstanding	n/a
Shares Change (YoY)	+18.64%
Shares Change (QoQ)	-2.99%
Owned by Insiders (%)	15.26%
Owned by Institutions (%)	1.72%
Float	63.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	115.75
PS Ratio	33.70
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-85.22
EV / Sales	31.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.03

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-14.59%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	6.25%
Revenue Per Employee	183,702
Profits Per Employee	-68,800
Employee Count	47
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-2.24M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +130.03% in the last 52 weeks. The beta is 0.36, so Oryzon Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.36
52-Week Price Change	+130.03%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	58.47
Average Volume (20 Days)	2,577

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oryzon Genomics had revenue of 8.63 million and -3.23 million in losses. Loss per share was -0.04.

Revenue	8.63M
Gross Profit	8.28M
Operating Income	-8.67M
Pretax Income	-5.47M
Net Income	-3.23M
EBITDA	-8.52M
EBIT	-8.67M
Loss Per Share	-0.04

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 95.89%, with operating and profit margins of -100.44% and -37.45%.

Gross Margin	95.89%
Operating Margin	-100.44%
Pretax Margin	-63.35%
Profit Margin	-37.45%
EBITDA Margin	-98.71%
EBIT Margin	-100.44%
FCF Margin	n/a

Dividends & Yields

Oryzon Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.64%
Shareholder Yield	-18.64%
Earnings Yield	-1.11%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a